InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, held its 15th Annual Internal Scientific Meeting. The Meeting traditionally passed in warm, friendly atmosphere and the discussion was efficient and uniting.

Oleg Demin, Chief Scientific Advisor and co-founder of InSysBio, opened the Meeting by the overview of QSP modeling as an important methodology and one of directions of Pharmacometrics development through time. Moreover, Oleg Demin covered InSysBio’s advancement of the year 2024. In 2024 InSysBio developed QSP modeling projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. InSysBio focused on such therapeutic areas as oncology, immunology, immune-oncology, neurodegenerative diseases and rare diseases. InSysBio team presented the results of 2024 performance and all team members shared their own contributions to various projects. The presentations were followed by the discussion of the outlook and further development ideas.

Moreover, InSysBio’s own fully-fledged QSP infrastructure that includes QSP softs (Heta, Likelihood Profiler), databases (CYTOCON DB, fIVE DB) and tools (IRT) was supplemented by Cloud infrastructure for multiple simulations. All of them were significantly enhanced throughout the year and further update is underway. In 2024 InSysBio presented its QSP modeling services and software to optimize drug development at ASCPT 2024, PAGE 2024, JuliaCon2024, SITC 2024 and ACoP 2024.

The perspective outlook shows that the company has intention towards constant growth. This year InSysBio has already presented its results at AACR 2025 and is going to participate in PAGE 2025 and ACoP 2025.

About InSysBio

InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com

Share